QIAGEN NV

What they make

3 inputs QIAGEN NV supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

2 facilities

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Note2024

  In March 2020, Thermo Fisher Scientific made a $11.5 billion acquisition offer for Qiagen — a move that would have combined the #1 and #2 RNA extraction companies into a single entity. The deal was abandoned in August 2020 after Qiagen shareholders did not reach the 66.7% tender threshold, partly because Qiagen's COVID windfall made shareholders reluctant to sell. Had the deal closed, a single company would have controlled ~60% of global RNA extraction kit supply — the most concentrated possible outcome for a supply chain already identified as a critical pandemic vulnerability.

  Mordor Intelligence ↗

• Did you know2023

  QIAGEN's DNA/RNA extraction kits — designed primarily for clinical molecular diagnostics (COVID testing, HIV monitoring, cancer mutation detection) — are also the reference standard for forensic DNA analysis in crime labs globally. The FBI, UK National DNA Database (NDNAD), and European crime labs use QIAGEN QIAamp extraction kits for processing crime scene evidence. The QIAsymphony SP automated extraction robot processes 96 evidence samples simultaneously — enabling state crime labs to reduce DNA backlog. Investigative genetic genealogy (IGG) programs like those that solved the Golden State Killer case use QIAGEN extraction to obtain DNA from decades-old evidence. The same silica spin column chemistry that identifies COVID viral RNA in a hospital nasopharyngeal swab within 30 minutes is the same chemistry that extracts DNA from a 35-year-old blood stain at a crime scene.

  QIAGEN NV ↗

• Capacity2023

  QIAGEN's QuantiFERON-TB Gold Plus (QFT) test is the dominant global diagnostic for latent tuberculosis infection (LTBI) — detecting whether someone has been infected with TB even if they don't have active disease. With 10 million new active TB cases and 1.5 million deaths per year, TB testing is a massive global public health need. QFT is used in healthcare worker screening, immigration processing, and pre-immunosuppressive therapy screening. QIAGEN performs over 50 million QFT tests annually. A company known for its COVID and molecular biology kits is also the backbone of global tuberculosis surveillance — an entirely separate infectious disease pipeline using QIAGEN's automation infrastructure.

  QIAGEN NV ↗

• Origin2023

  QIAGEN was founded in 1984 in Düsseldorf, Germany by Metin Colpan and colleagues at the Heinrich Heine University, commercializing a novel silica membrane-based DNA/RNA purification technology. The core innovation was replacing cesium chloride density gradient ultracentrifugation (the gold standard of the time) with a spin column containing silica beads and chaotropic salts — reducing DNA extraction from a 2-day, multi-step procedure requiring an ultracentrifuge to a 30-minute bench-top protocol. This democratization of molecular biology sample preparation made PCR-based diagnostics practical for routine clinical use. QIAGEN listed on NYSE in 1996 and subsequently acquired >50 companies to build its current portfolio. Thermo Fisher Scientific launched a $11.5B hostile takeover in March 2020 — timed to capture COVID demand — but withdrew in August 2020 citing COVID supply uncertainty ironically, as QIAGEN's WHO-standard COVID kits were supply-constrained.

  QIAGEN NV ↗